MYC and urinary bladder cancer: The activating mutations of FGFR3 have been shown to promote a positive feedback in FGFR3 expression through the stabilisation of Myc (Myc proto-oncogene protein), resulting in the upregulation of FGFR3 in bladder cancers [39].